Vaccine Makers Weigh Benefits Of Seasonal Influenza Versus Swine Flu Via “Educated Guess”
This article was originally published in PharmAsia News
Executive Summary
HONG KONG - Even if all the necessary elements to make a swine flu vaccine are in place or to ramp up production of anti-viral drugs, multinational drug companies may see little upside in actually doing either
You may also be interested in...
Developing A Pandemic Vaccine Is A Race Against Time, Says IFPMA Director General
HONG KONG - Global vaccine makers are ready to mass-produce vaccines for H1N1 as soon as health authorities need, says the head of the global association that represents multinational vaccine makers
Developing A Pandemic Vaccine Is A Race Against Time, Says IFPMA Director General
HONG KONG - Global vaccine makers are ready to mass-produce vaccines for H1N1 as soon as health authorities need, says the head of the global association that represents multinational vaccine makers
China Produces Tamiflu And Relenza Locally To Prepare For Swine Flu
China's health and relevant authorities are gearing up to tackle the rapidly spreading swine flu. Besides stockpiling Roche's Tamiflu and GSK's Relenza, the country is producing the drugs locally. During the 2005 bird flu outbreak, Roche and GSK authorized Shanghai Pharmaceutical and Guangdong Oriental Sunshine Pharmaceuticals to manufacture their drugs, and Simcere to localize the production. With an annual output of 200 million Tamiflu tablets, Guangdong Oriental Sunshine has the largest production capability worldwide and has received purchase orders from provincial governments such as Guangdong, Hubei and Anhui. Shanghai Pharmaceutical said it will start production upon receiving orders. Meanwhile, Simcere is planning to ask China's State FDA to fast-track the approval for its clinical trial, which was suspended when the avian outbreak did not occur. (Click here for more - Chinese language)